Difference between revisions of "Bleeding with anticoagulation"
Jump to navigation
Jump to search
Tag: visualeditor |
m |
||
Line 1: | Line 1: | ||
− | + | ''The purpose of this page will be to focus on toxicity of anticoagulation, i.e., bleeding. It will be further organized over time.'' | |
− | The purpose of this page will be to focus on toxicity of anticoagulation, i.e., bleeding. It will be further organized | ||
− | = | + | =[[Apixaban (Eliquis)]] reversal= |
− | == | + | ==[[Factor Xa, recombinant, inactivated-zhzo (Andexxa)]]== |
− | *[[Factor Xa, recombinant, inactivated-zhzo (Andexxa)]] | + | *[[Factor Xa, recombinant, inactivated-zhzo (Andexxa)]] as follows: |
− | ** | + | **Apixaban dose up to 5 mg: 400 mg IV bolus at a target rate of 30 mg/min then 480 mg IV infusion at a rate of 4 mg/min for 2 hours |
− | ** | + | **Apixaban dose greater than 5mg or unknown but at least 8 hours since last administration: 400 mg IV bolus at a target rate of 30 mg/min then 480 mg IV infusion at a rate of 4 mg/min for 2 hours |
− | ** | + | **Apixaban dose greater than 5mg or unknown and less than 8 hours since last administration: 800mg IV bolus at a target rate of 30 mg/min then 960 mg IV infusion at a rate of 8 mg/min for 2 hours |
+ | ===References=== | ||
− | = | + | =[[Dabigatran (Pradaxa)]] reversal= |
− | + | ==[[Idarucizumab (Praxbind)]]== | |
+ | *To be completed | ||
− | = | + | =[[Dalteparin (Fragmin)]] reversal= |
− | + | ==[[Protamine sulfate (USP)]]== | |
+ | *To be completed | ||
− | = | + | =[[Enoxaparin (Lovenox)]] reversal= |
− | + | ==[[Protamine sulfate (USP)]]== | |
+ | *To be completed | ||
− | = | + | =[[Heparin]] reversal= |
− | + | ==[[Protamine sulfate (USP)]]== | |
+ | *To be completed | ||
− | = | + | =[[Rivaroxaban (Xarelto)]] reversal= |
− | *[[Factor Xa, recombinant, inactivated-zhzo (Andexxa)]] | + | ==[[Factor Xa, recombinant, inactivated-zhzo (Andexxa)]]== |
− | ** | + | *[[Factor Xa, recombinant, inactivated-zhzo (Andexxa)]] as follows: |
− | ** | + | **Rivaroxaban dose up to 10mg: 400 mg IV bolus at a target rate of 30 mg/min then 480 mg IV infusion at a rate of 4 mg/min for 2 hours |
− | ** | + | **Rivaroxaban dose greater than 10mg or unknown but at least 8 hours since last administration: 400 mg IV bolus at a target rate of 30 mg/min then 480 mg IV infusion at a rate of 4 mg/min for 2 hours |
+ | **Rivaroxaban dose greater than 10mg or unknown and less than 8 hours since last administration: 800mg IV bolus at a target rate of 30 mg/min then 960 mg IV infusion at a rate of 8 mg/min for 2 hours | ||
+ | ===References=== | ||
− | = | + | =[[Warfarin (Coumadin)]] reversal= |
− | + | ==Fresh frozen plasma (FFP)== | |
− | + | ==[[Prothrombin Complex Concentrate, Human (Kcentra)]]== | |
− | == | + | =Perioperative management= |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | == | + | =Bleeding risk calculators= |
− | |||
*Bleeding risk on anticoagulation: [http://www.globalrph.com/has-bled-score.htm HAS-BLED]; [http://www.globalrph.com/hemorr2hages-bleeding-risk.htm HEMORR2HAGES] | *Bleeding risk on anticoagulation: [http://www.globalrph.com/has-bled-score.htm HAS-BLED]; [http://www.globalrph.com/hemorr2hages-bleeding-risk.htm HEMORR2HAGES] | ||
[[Category:General reference pages]] | [[Category:General reference pages]] | ||
[[Category:Bleeding disorders]] | [[Category:Bleeding disorders]] |
Revision as of 02:30, 28 May 2018
The purpose of this page will be to focus on toxicity of anticoagulation, i.e., bleeding. It will be further organized over time.
Apixaban (Eliquis) reversal
Factor Xa, recombinant, inactivated-zhzo (Andexxa)
- Factor Xa, recombinant, inactivated-zhzo (Andexxa) as follows:
- Apixaban dose up to 5 mg: 400 mg IV bolus at a target rate of 30 mg/min then 480 mg IV infusion at a rate of 4 mg/min for 2 hours
- Apixaban dose greater than 5mg or unknown but at least 8 hours since last administration: 400 mg IV bolus at a target rate of 30 mg/min then 480 mg IV infusion at a rate of 4 mg/min for 2 hours
- Apixaban dose greater than 5mg or unknown and less than 8 hours since last administration: 800mg IV bolus at a target rate of 30 mg/min then 960 mg IV infusion at a rate of 8 mg/min for 2 hours
References
Dabigatran (Pradaxa) reversal
Idarucizumab (Praxbind)
- To be completed
Dalteparin (Fragmin) reversal
Protamine sulfate (USP)
- To be completed
Enoxaparin (Lovenox) reversal
Protamine sulfate (USP)
- To be completed
Heparin reversal
Protamine sulfate (USP)
- To be completed
Rivaroxaban (Xarelto) reversal
Factor Xa, recombinant, inactivated-zhzo (Andexxa)
- Factor Xa, recombinant, inactivated-zhzo (Andexxa) as follows:
- Rivaroxaban dose up to 10mg: 400 mg IV bolus at a target rate of 30 mg/min then 480 mg IV infusion at a rate of 4 mg/min for 2 hours
- Rivaroxaban dose greater than 10mg or unknown but at least 8 hours since last administration: 400 mg IV bolus at a target rate of 30 mg/min then 480 mg IV infusion at a rate of 4 mg/min for 2 hours
- Rivaroxaban dose greater than 10mg or unknown and less than 8 hours since last administration: 800mg IV bolus at a target rate of 30 mg/min then 960 mg IV infusion at a rate of 8 mg/min for 2 hours
References
Warfarin (Coumadin) reversal
Fresh frozen plasma (FFP)
Prothrombin Complex Concentrate, Human (Kcentra)
Perioperative management
Bleeding risk calculators
- Bleeding risk on anticoagulation: HAS-BLED; HEMORR2HAGES